Code-named AP23573 and now in middle-phase trials of 176 patients, it is aimed at an awfully small market:Only 12, 000 to 13, 000 new cases of sarcoma are diagnosed each year, compared with 213, 000 new cases of breast cancer.

FORBES: Mission Improbable